MUNICH, Germany, August 31 /PRNewswire/ --
Press conference The BEAUTIFUL study: a step further in
title Coronary Artery Disease
ESC Hotline Title: The BEAUTIFUL study: efficacy of
session title ivabradine in reduction of cardiovascular
events among patients with stable coronary
artery disease and left ventricular
ESC Hotline 31st August 2008, 11:18 - 11:31 AM
Press conference 9.00-10.00
Executive 31st August 2008: 9.00 - 10.30 AM
The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the IF inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy. Commenting after the results presentation, the Chairman of the BEAUTIFUL Executive Committee, Prof Kim Fox said, "Ivabradine was always known to relieve ischemia. With the BEAUTIFUL results, ivabradine is the first antianginal treatment shown to reduce myocardial infarction and revascularisation and to have a good tolerability profile even when used with other drugs. This is the gold standard for any antianginal, anti-ischemic drug."
The BEAUTIFUL trial was initiated in December 2004, under the guidance
of an independent Executive Committee with the f
|SOURCE Executive Committee of Beautiful Study|
Copyright©2008 PR Newswire.
All rights reserved